Oculogenetic highlights include advances in therapy, technology

Article

Highlighting the many developments in the area of oculogenetics, Edwin M. Stone, MD, PhD, is concentrating on a gene therapy experiment.

Iowa City, IA-Highlighting the many developments from the burgeoning field of oculogenetics, Edwin M. Stone, MD, PhD, chose to concentrate on a successful gene therapy experiment, the increasing availability of clinical trials, and new technology that enhances genetic testing.

"We're excited about that, not just because of this disease, but because of the way it seems to be leading the way toward gene replacement therapy for a lot of other diseases," said Dr. Stone, professor of ophthalmology, Howard Hughes Medical Institute Investigator, and holder of the Seamans-Hauser Chair in molecular ophthalmology at the University of Iowa, Iowa City. (For further information about the University of Iowa's Department of Ophthalmology and Visual Sciences, see "Clinical Centers of Excellence" of this issue.)

A third important development is advanced technology, specifically a combination of allele-specific testing and next-generation deep sequencing that is much faster and more accurate than older methods.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.